These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34474468)

  • 1. Perspective of structural flexibility on selective inhibition towards CYP1B1 over CYP1A1 by α-naphthoflavone analogs.
    Wang Y; Hu B; Zhang Y; Wang D; Luo Z; Wang J; Zhang F
    Phys Chem Chem Phys; 2021 Sep; 23(36):20230-20246. PubMed ID: 34474468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of selective CYP1B1 inhibitor via dearomatization of α-naphthoflavone.
    Kubo M; Yamamoto K; Itoh T
    Bioorg Med Chem; 2019 Jan; 27(2):285-304. PubMed ID: 30553624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationship studies of α-naphthoflavone derivatives as CYP1B1 inhibitors.
    Dong J; Wang Z; Cui J; Meng Q; Li S
    Eur J Med Chem; 2020 Feb; 187():111938. PubMed ID: 31830634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of human CYP1 enzymes by a classical inhibitor α-naphthoflavone and a novel inhibitor N-(3, 5-dichlorophenyl)cyclopropanecarboxamide: An in vitro and in silico study.
    Juvonen RO; Jokinen EM; Javaid A; Lehtonen M; Raunio H; Pentikäinen OT
    Chem Biol Drug Des; 2020 May; 95(5):520-533. PubMed ID: 32060993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of CYP1B1-specific candidate inhibitors using combination of in silico screening, integrated knowledge-based filtering, and molecular dynamics simulations.
    Kumar R; Gupta D
    Chem Biol Drug Des; 2016 Nov; 88(5):730-739. PubMed ID: 27300691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of heterocycle-containing α-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors.
    Dong J; Huang G; Cui Q; Meng Q; Li S; Cui J
    Eur J Med Chem; 2021 Jan; 209():112895. PubMed ID: 33069055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Synthesis of New α-Naphthoflavones as Cytochrome P450 (CYP) 1B1 Inhibitors To Overcome Docetaxel-Resistance Associated with CYP1B1 Overexpression.
    Cui J; Meng Q; Zhang X; Cui Q; Zhou W; Li S
    J Med Chem; 2015 Apr; 58(8):3534-47. PubMed ID: 25799264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship.
    Chen P; Wang S; Cao C; Ye W; Wang M; Zhou C; Chen W; Zhang X; Zhang K; Zhou W
    Bioorg Chem; 2021 Nov; 116():105295. PubMed ID: 34455300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance.
    Sonawane VR; Siddique MUM; Gatchie L; Williams IS; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B
    Eur J Pharm Sci; 2019 Apr; 131():177-194. PubMed ID: 30776468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of differences in substrate specificity among CYP1A1, CYP1A2 and CYP1B1: an integrated approach employing molecular docking and molecular dynamics simulations.
    Kesharwani SS; Nandekar PP; Pragyan P; Rathod V; Sangamwar AT
    J Mol Recognit; 2016 Aug; 29(8):370-90. PubMed ID: 26916064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new class of CYP1B1 inhibitors derived from bentranil.
    Yi L; Huang X; Yang M; Cai J; Jia J; Peng Z; Zhao Z; Yang F; Qiu D
    Bioorg Med Chem Lett; 2023 Jan; 80():129112. PubMed ID: 36565966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1.
    Don MJ; Lewis DF; Wang SY; Tsai MW; Ueng YF
    Bioorg Med Chem Lett; 2003 Aug; 13(15):2535-8. PubMed ID: 12852960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitidine Chloride-Induced CYP1 Enzyme Inhibition and Alteration of Estradiol Metabolism.
    Mao X; Wang J; Wang Q; Yang L; Li Y; Lin H; Peng Y; Zheng J
    Drug Metab Dispos; 2019 Aug; 47(8):919-927. PubMed ID: 31147316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.
    Lee D; Perez P; Jackson W; Chin T; Galbreath M; Fronczek FR; Isovitsch R; Iimoto DS
    Bioorg Med Chem Lett; 2016 Jul; 26(14):3243-3247. PubMed ID: 27265259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple machine learning, molecular docking, and ADMET screening approach for identification of selective inhibitors of CYP1B1.
    Raju B; Verma H; Narendra G; Sapra B; Silakari O
    J Biomol Struct Dyn; 2022 Oct; 40(17):7975-7990. PubMed ID: 33769194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Synthesis of Chalcones as Anticancer Prodrugs and their Bioactivation in CYP1 Expressing Breast Cancer Cells.
    Ruparelia KC; Zeka K; Ijaz T; Ankrett DN; Wilsher NE; Butler PC; Tan HL; Lodhi S; Bhambra AS; Potter GA; Arroo RRJ; Beresford KJM
    Med Chem; 2018; 14(4):322-332. PubMed ID: 29332599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells.
    Chua MS; Kashiyama E; Bradshaw TD; Stinson SF; Brantley E; Sausville EA; Stevens MF
    Cancer Res; 2000 Sep; 60(18):5196-203. PubMed ID: 11016648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biphenyl urea derivatives as selective CYP1B1 inhibitors.
    Mohd Siddique MU; McCann GJ; Sonawane V; Horley N; Williams IS; Joshi P; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B
    Org Biomol Chem; 2016 Sep; 14(38):8931-8936. PubMed ID: 27714268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Potent and Selective CYP1A1 Inhibitors via Combined Ligand and Structure-Based Virtual Screening and Their in Vitro Validation in Sacchrosomes and Live Human Cells.
    Joshi P; McCann GJP; Sonawane VR; Vishwakarma RA; Chaudhuri B; Bharate SB
    J Chem Inf Model; 2017 Jun; 57(6):1309-1320. PubMed ID: 28489395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico guided designing of optimized benzochalcones derivatives as potent CYP1B1 inhibitors: An integrated in vitro and ONIOM study.
    Sharma H; Raju B; Narendra G; Kumar M; Verma H; Sharma B; Tung GK; Kumar Jain S; Brás NF; Silakari O
    J Mol Graph Model; 2023 Mar; 119():108390. PubMed ID: 36502606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.